Biogen Reports 10th PML Case With Tysabri
This morning, Deutsche Bank biotech analyst Mark Schoenebaum downgraded Biogen Idec to hold from buy because the stock at $50 "is now pricing in reasonable Tysabri expectations and no longer warrants being one of our 'top picks' in 2009."
Elan shares closed Friday at $7.96. Novartis is reportedly in negotiations to acquire a stake in the Irish drug maker, according to a Reuters report over the weekend.- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
Connect with TheStreet
 |
 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,388.90 | 1,105.98 | 2,194.35 | 34.83 |
Oil *
77.74
|
|
UP
22.75
|
UP
6.06
|
UP
21.21
|
UP
1.03
|
10 Yr
3.48%
SPDR Gold
113.75
|
|
+0.22%
|
+0.55%
|
+0.98%
|
+3.05%
|
Data delayed 20 minutes |
